A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
